Showing 8,381 - 8,400 results of 32,364 for search '(( 50 ((ng decrease) OR (((we decrease) OR (a decrease)))) ) OR ( e point decrease ))', query time: 1.12s Refine Results
  1. 8381
  2. 8382

    Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects by Xiaopeng Peng (9136955)

    Published 2022
    “…Importantly, the combination of <b>NT-6</b> with a small-molecule PD-L1 inhibitor NP-19 decreased tumor burden significantly (TGI% = 77.6%). …”
  3. 8383

    Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects by Xiaopeng Peng (9136955)

    Published 2022
    “…Importantly, the combination of <b>NT-6</b> with a small-molecule PD-L1 inhibitor NP-19 decreased tumor burden significantly (TGI% = 77.6%). …”
  4. 8384
  5. 8385
  6. 8386
  7. 8387
  8. 8388
  9. 8389
  10. 8390
  11. 8391

    Strong matrix metalloproteinase (MMP)-2/9-related near-infrared fluorescent (NIRF) signal in and around the ligated area of the left common carotid artery (LCA) of ApoE<sup>-/-</su... by Ik Jae Shin (387313)

    Published 2013
    “…<p>Two weeks after partial ligation of the LCA, there is a gradient of MMP-related fluorescence (mean intensity / tissue area in a rectangular region of interest) that is maximal close to the ligation site / bifurcation point (A, LCA C1 or C2), and progressively decreased as one move inferiorly closer to the arch both on the right and on the left, but the maximum is much higher on the ligated left side (A and B). …”
  12. 8392

    DataSheet1_The Variants at APOA1 and APOA4 Contribute to the Susceptibility of Schizophrenia With Inhibiting mRNA Expression in Peripheral Blood Leukocytes.pdf by Yao Fan (1977274)

    Published 2021
    “…After the SZ patients received an average of 27.50 ± 9.90 days of antipsychotic treatment, the median (interquartile) of serum apoA1 in the SZ episode significantly increased from 1.03 (1.00.1.20) g/L to 1.08 (1.00.1.22) g/L with the p-value of 0.044.…”
  13. 8393
  14. 8394
  15. 8395
  16. 8396
  17. 8397
  18. 8398

    Discovery of 2‑Ethoxy-5-isobutyramido‑<i>N</i>‑1-substituted Benzamide Derivatives as Selective Kv2.1 Inhibitors with In Vivo Neuroprotective Effects by Jie Zhou (28945)

    Published 2023
    “…In this work, a series of novel benzamide derivatives were designed and synthesized as Kv2.1 inhibitors, and extensive structure–activity relationships led to highly potent and selective Kv2.1 inhibitors having IC<sub>50</sub> values of 10<sup>–8</sup> M. …”
  19. 8399

    Discovery of 2‑Ethoxy-5-isobutyramido‑<i>N</i>‑1-substituted Benzamide Derivatives as Selective Kv2.1 Inhibitors with In Vivo Neuroprotective Effects by Jie Zhou (28945)

    Published 2023
    “…In this work, a series of novel benzamide derivatives were designed and synthesized as Kv2.1 inhibitors, and extensive structure–activity relationships led to highly potent and selective Kv2.1 inhibitors having IC<sub>50</sub> values of 10<sup>–8</sup> M. …”
  20. 8400

    Discovery of 2‑Ethoxy-5-isobutyramido‑<i>N</i>‑1-substituted Benzamide Derivatives as Selective Kv2.1 Inhibitors with In Vivo Neuroprotective Effects by Jie Zhou (28945)

    Published 2023
    “…In this work, a series of novel benzamide derivatives were designed and synthesized as Kv2.1 inhibitors, and extensive structure–activity relationships led to highly potent and selective Kv2.1 inhibitors having IC<sub>50</sub> values of 10<sup>–8</sup> M. …”